Cargando…

Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Min, Wang, Liying, Wang, Ying, Wang, Xu, Lei, Jiaxi, Cheng, Xixi, Feng, Yu, Hou, Yanyan, Wang, Qian, Xue, Chuizhao, Gavotte, Laurent, Frutos, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236642/
https://www.ncbi.nlm.nih.gov/pubmed/37274767
http://dx.doi.org/10.46234/ccdcw2023.083
_version_ 1785052982200500224
author Qin, Min
Wang, Liying
Wang, Ying
Wang, Xu
Lei, Jiaxi
Cheng, Xixi
Feng, Yu
Hou, Yanyan
Wang, Qian
Xue, Chuizhao
Gavotte, Laurent
Frutos, Roger
author_facet Qin, Min
Wang, Liying
Wang, Ying
Wang, Xu
Lei, Jiaxi
Cheng, Xixi
Feng, Yu
Hou, Yanyan
Wang, Qian
Xue, Chuizhao
Gavotte, Laurent
Frutos, Roger
author_sort Qin, Min
collection PubMed
description WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS ADDED BY THIS REPORT? This study reviewed the medical records of 899 patients who underwent albendazole treatment across 10 endemic counties. Out of 634 evaluable patient files, the proportion of patients with a ratio of actual follow-up and reexamination times to theoretical follow-up and reexamination times ≥0.8 were both low (21.92% and 23.19%, respectively). WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES? This study identified weaknesses and specific issues in patient management and proposed feasible recommendations to enhance patient file documentation, follow-up, and reexamination.
format Online
Article
Text
id pubmed-10236642
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-102366422023-06-03 Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 Qin, Min Wang, Liying Wang, Ying Wang, Xu Lei, Jiaxi Cheng, Xixi Feng, Yu Hou, Yanyan Wang, Qian Xue, Chuizhao Gavotte, Laurent Frutos, Roger China CDC Wkly Preplanned Studies WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS ADDED BY THIS REPORT? This study reviewed the medical records of 899 patients who underwent albendazole treatment across 10 endemic counties. Out of 634 evaluable patient files, the proportion of patients with a ratio of actual follow-up and reexamination times to theoretical follow-up and reexamination times ≥0.8 were both low (21.92% and 23.19%, respectively). WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES? This study identified weaknesses and specific issues in patient management and proposed feasible recommendations to enhance patient file documentation, follow-up, and reexamination. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023-05-19 /pmc/articles/PMC10236642/ /pubmed/37274767 http://dx.doi.org/10.46234/ccdcw2023.083 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Preplanned Studies
Qin, Min
Wang, Liying
Wang, Ying
Wang, Xu
Lei, Jiaxi
Cheng, Xixi
Feng, Yu
Hou, Yanyan
Wang, Qian
Xue, Chuizhao
Gavotte, Laurent
Frutos, Roger
Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title_full Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title_fullStr Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title_full_unstemmed Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title_short Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
title_sort investigation on the management for patients with echinococcosis treated with albendazole — three plads, china, 2019
topic Preplanned Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236642/
https://www.ncbi.nlm.nih.gov/pubmed/37274767
http://dx.doi.org/10.46234/ccdcw2023.083
work_keys_str_mv AT qinmin investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT wangliying investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT wangying investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT wangxu investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT leijiaxi investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT chengxixi investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT fengyu investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT houyanyan investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT wangqian investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT xuechuizhao investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT gavottelaurent investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019
AT frutosroger investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019